Dr. Hope on Benefits of Gallium 68-Dotatate PET Scan

Thomas Hope, MD
Published: Friday, Jan 27, 2017



Thomas Hope, MD, assistant professor, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the Gallium 68-Dotatate PET scan in the imaging of neuroendocrine tumors (NETs).

Imaging for NETs is difficult as they are slow growing, requiring very sensitive imaging studies. Commonly, the octreoscan has been used in practice to track these tumors, which targets somatostatin receptors.

Recently, the Gallium-68 dotatate scan that is labeled with Gallium-68, a radionuclide, has demonstrated much higher sensitivity for both detection and characterization of NETs.

While the cost is high, the benefits outweigh this, says Hope. Octreoscan takes a minimum 1 2 days to complete, while a Gallium-68 dotatate scan takes about 1 hour to conduct after injection. Also, the improved imaging allows physicians to more accurately track patients over time.
 
SELECTED
LANGUAGE


Thomas Hope, MD, assistant professor, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the Gallium 68-Dotatate PET scan in the imaging of neuroendocrine tumors (NETs).

Imaging for NETs is difficult as they are slow growing, requiring very sensitive imaging studies. Commonly, the octreoscan has been used in practice to track these tumors, which targets somatostatin receptors.

Recently, the Gallium-68 dotatate scan that is labeled with Gallium-68, a radionuclide, has demonstrated much higher sensitivity for both detection and characterization of NETs.

While the cost is high, the benefits outweigh this, says Hope. Octreoscan takes a minimum 1 2 days to complete, while a Gallium-68 dotatate scan takes about 1 hour to conduct after injection. Also, the improved imaging allows physicians to more accurately track patients over time.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
Community Practice Connections™: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical ExperienceJan 31, 20192.0
Publication Bottom Border
Border Publication
x